China Rare Biomarkers Specimen Collection And Stabilization Market Size & Outlook
China rare biomarkers specimen collection and stabilization market, 2018-2030 (US$M)
Related Markets
China rare biomarkers specimen collection and stabilization market highlights
- The China rare biomarkers specimen collection and stabilization market generated a revenue of USD 2,143.7 million in 2024 and is expected to reach USD 5,252.2 million by 2030.
- The China market is expected to grow at a CAGR of 16.4% from 2025 to 2030.
- In terms of segment, circulating cell free dna (ccfdna) was the largest revenue generating biomarker in 2024.
- Circulating Cell Free RNA (ccfRNA) / miRNA is the most lucrative biomarker segment registering the fastest growth during the forecast period.
Rare biomarkers specimen collection and stabilization market data book summary
| Market revenue in 2024 | USD 2,143.7 million |
| Market revenue in 2030 | USD 5,252.2 million |
| Growth rate | 16.4% (CAGR from 2025 to 2030) |
| Largest segment | Circulating cell free dna (ccfdna) |
| Fastest growing segment | Circulating Cell Free RNA (ccfRNA) / miRNA |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes/Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA |
| Key market players worldwide | Qiagen NV, Charles River Laboratories International Inc, Roche Holding AG ADR, Thermo Fisher Scientific Inc, Eurofins Scientific SE, PerkinElmer, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Merck KGaA, Siemens Healthineers AG ADR |
Other key industry trends
- In terms of revenue, China accounted for 5.1% of the global rare biomarkers specimen collection and stabilization market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China rare biomarkers specimen collection and stabilization market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 3,190.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Rare Biomarkers Specimen Collection And Stabilization Market Scope
Rare Biomarkers Specimen Collection And Stabilization Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China rare biomarkers specimen collection and stabilization market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare biomarkers specimen collection and stabilization market will help companies and investors design strategic landscapes.
Circulating cell free dna (ccfdna) was the largest segment with a revenue share of 40.76% in 2024. Horizon Databook has segmented the China rare biomarkers specimen collection and stabilization market based on circulating cell free dna (ccfdna), circulating tumor cells (ctcs), exosomes/extracellular vesicles, circulating cell free rna (ccfrna) / mirna covering the revenue growth of each sub-segment from 2018 to 2030.
End users are signing purchase agreements with technology providers, which is expected to positively influence the revenue growth in this country. For instance, in January 2020, Kindstar Global, a China-based medical esoteric testing service group, collaborated with Celsee, Inc., a provider of single-cell isolation technology.
To provide scientists at the Kindstar Laboratory System with Celsee’s Genesis System to assess CTCs in bladder, breast, and lung cancers as well as single-cell research. Moreover, presence of China FDA-approved CTC test for diagnosis and monitoring of metastatic cancer is one of the key contributors to the revenue generation in the market.
In June 2018, Vela Diagnostics secured approval for its Sentosa SX Cell-free DNA kit from China FDA. The kit is designed to extract cffDNA from plasma for downstream assays, such as PCR and sequencing workflows.
Reasons to subscribe to China rare biomarkers specimen collection and stabilization market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China rare biomarkers specimen collection and stabilization market databook
-
Our clientele includes a mix of rare biomarkers specimen collection and stabilization market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China rare biomarkers specimen collection and stabilization market , including forecasts for subscribers. This country databook contains high-level insights into China rare biomarkers specimen collection and stabilization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China rare biomarkers specimen collection and stabilization market size, by biomarker, 2018-2030 (US$M)
China Rare Biomarkers Specimen Collection And Stabilization Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
